BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37813479)

  • 1. PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
    Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
    Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
    RAINBO Research Consortium
    Int J Gynecol Cancer; 2022 Dec; 33(1):109-17. PubMed ID: 36600534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
    León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
    J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
    van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
    Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).
    Grassi T; Mariani A; Cibula D; Soliman PT; Suman VJ; Weaver AL; Pedra Nobre S; Weigelt B; Glaser GE; Cappuccio S; Abu-Rustum NR
    Int J Gynecol Cancer; 2020 Oct; 30(10):1627-1632. PubMed ID: 32699021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
    Li Y; Zhu C; Xie H; Chen Y; Lv W; Xie X; Wang X
    J Gynecol Oncol; 2023 Mar; 34(2):e37. PubMed ID: 36659832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
    Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
    Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
    Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
    Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
    Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
    J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
    D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
    Wortman BG; Bosse T; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld H; van den Berg H; Slot A; De Winter KAJ; Verhoeven-Adema KW; Smit VTHBM; Creutzberg CL;
    Gynecol Oncol; 2018 Oct; 151(1):69-75. PubMed ID: 30078506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6).
    Emons G; Kim JW; Weide K; de Gregorio N; Wimberger P; Trillsch F; Gabriel B; Denschlag D; Kommoss S; Aydogdu M; Papathemelis T; Gropp-Meier M; Muallem MZ; Kühn C; Müller A; Frank M; Weigel M; Bronger H; Lampe B; Rau J; Schade-Brittinger C; Harter P
    Int J Gynecol Cancer; 2021 Jul; 31(7):1075-1079. PubMed ID: 34226291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
    Knez J; Sobocan M; Belak U; Kavalar R; Zupin M; Büdefeld T; Potocnik U; Takac I
    Radiol Oncol; 2021 Sep; 56(1):76-82. PubMed ID: 34529911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular classification of endometrial carcinoma, is it the new era of precision medicine?
    Bidzinski M; Danska-Bidzinska A; Rychlik A; Kypryjanczyk J; Pyzlak M; Piatek S
    Ginekol Pol; 2022; 93(2):163-167. PubMed ID: 35072255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant radiotherapy for stage I endometrial cancer.
    Kong A; Johnson N; Kitchener HC; Lawrie TA
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003916. PubMed ID: 22513918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial Cancer: Transitioning from Histology to Genomics.
    Mitric C; Bernardini MQ
    Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma.
    Krämer P; Talhouk A; Brett MA; Chiu DS; Cairns ES; Scheunhage DA; Hammond RFL; Farnell D; Nazeran TM; Grube M; Xia Z; Senz J; Leung S; Feil L; Pasternak J; Dixon K; Hartkopf A; Krämer B; Brucker S; Heitz F; du Bois A; Harter P; Kommoss FKF; Sinn HP; Heublein S; Kommoss F; Vollert HW; Manchanda R; de Kroon CD; Nijman HW; de Bruyn M; Thompson EF; Bashashati A; McAlpine JN; Singh N; Tinker AV; Staebler A; Bosse T; Kommoss S; Köbel M; Anglesio MS
    Clin Cancer Res; 2020 Oct; 26(20):5400-5410. PubMed ID: 32737030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
    Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
    Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.